GB201815549D0 - Arginase1 polypeptides - Google Patents

Arginase1 polypeptides

Info

Publication number
GB201815549D0
GB201815549D0 GBGB1815549.9A GB201815549A GB201815549D0 GB 201815549 D0 GB201815549 D0 GB 201815549D0 GB 201815549 A GB201815549 A GB 201815549A GB 201815549 D0 GB201815549 D0 GB 201815549D0
Authority
GB
United Kingdom
Prior art keywords
arginase1
polypeptides
arginase1 polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1815549.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Priority to GBGB1815549.9A priority Critical patent/GB201815549D0/en
Publication of GB201815549D0 publication Critical patent/GB201815549D0/en
Priority to EP19779801.0A priority patent/EP3856899A1/en
Priority to MX2021003441A priority patent/MX2021003441A/es
Priority to KR1020217010964A priority patent/KR20210091696A/ko
Priority to AU2019350356A priority patent/AU2019350356B9/en
Priority to SG11202102378WA priority patent/SG11202102378WA/en
Priority to CA3113004A priority patent/CA3113004A1/en
Priority to PCT/EP2019/075731 priority patent/WO2020064744A1/en
Priority to CN201980062504.7A priority patent/CN112771159B/zh
Priority to US17/278,838 priority patent/US12194081B2/en
Priority to JP2021516368A priority patent/JP7624388B2/ja
Priority to IL281762A priority patent/IL281762A/en
Priority to US18/935,162 priority patent/US20250205318A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
GBGB1815549.9A 2018-09-24 2018-09-24 Arginase1 polypeptides Ceased GB201815549D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1815549.9A GB201815549D0 (en) 2018-09-24 2018-09-24 Arginase1 polypeptides
JP2021516368A JP7624388B2 (ja) 2018-09-24 2019-09-24 アルギナーゼ１ポリペプチド
CA3113004A CA3113004A1 (en) 2018-09-24 2019-09-24 Arginase1 polypeptides
MX2021003441A MX2021003441A (es) 2018-09-24 2019-09-24 Polipeptidos de arginasa1.
KR1020217010964A KR20210091696A (ko) 2018-09-24 2019-09-24 아르기나제1 폴리펩타이드
AU2019350356A AU2019350356B9 (en) 2018-09-24 2019-09-24 Arginase1 polypeptides
SG11202102378WA SG11202102378WA (en) 2018-09-24 2019-09-24 Arginase1 polypeptides
EP19779801.0A EP3856899A1 (en) 2018-09-24 2019-09-24 Arginase1 polypeptides
PCT/EP2019/075731 WO2020064744A1 (en) 2018-09-24 2019-09-24 Arginase1 polypeptides
CN201980062504.7A CN112771159B (zh) 2018-09-24 2019-09-24 精氨酸酶1多肽
US17/278,838 US12194081B2 (en) 2018-09-24 2019-09-24 ARGINASE1 polypeptides
IL281762A IL281762A (en) 2018-09-24 2021-03-24 Arginase1 polypeptides
US18/935,162 US20250205318A1 (en) 2018-09-24 2024-11-01 Arginase1 polypeptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1815549.9A GB201815549D0 (en) 2018-09-24 2018-09-24 Arginase1 polypeptides

Publications (1)

Publication Number Publication Date
GB201815549D0 true GB201815549D0 (en) 2018-11-07

Family

ID=64024184

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1815549.9A Ceased GB201815549D0 (en) 2018-09-24 2018-09-24 Arginase1 polypeptides

Country Status (12)

Country Link
US (2) US12194081B2 (enExample)
EP (1) EP3856899A1 (enExample)
JP (1) JP7624388B2 (enExample)
KR (1) KR20210091696A (enExample)
CN (1) CN112771159B (enExample)
AU (1) AU2019350356B9 (enExample)
CA (1) CA3113004A1 (enExample)
GB (1) GB201815549D0 (enExample)
IL (1) IL281762A (enExample)
MX (1) MX2021003441A (enExample)
SG (1) SG11202102378WA (enExample)
WO (1) WO2020064744A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201818576D0 (en) 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
KR20240159833A (ko) 2022-02-24 2024-11-06 아이오 바이오테크 에이피에스 아르기나아제 2 백신

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5780286A (en) 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US20110111424A1 (en) 2001-06-21 2011-05-12 Cell Signaling Technology, Inc. Analysis of ubiquitinated polypeptides
WO2003038444A2 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Biomarkers of liver function
CA2836155A1 (en) 2004-10-29 2006-05-11 Board Of Trustees Of Michigan State University Protection against herbivores
CA2742497C (en) 2008-10-31 2024-01-23 George Georgiou Compositions of engineered human arginases and methods for treating cancer
CN101781369A (zh) * 2009-01-20 2010-07-21 江苏先声药物研究有限公司 一种重组人精氨酸酶融合蛋白及其应用
CN106456723B (zh) * 2014-04-29 2021-03-09 康达医药科技有限公司 采用精氨酸酶i调节免疫系统的方法和组合物
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
AU2017341112B2 (en) * 2016-10-07 2024-06-27 Io Biotech Aps Immunogenic arginase peptides

Also Published As

Publication number Publication date
WO2020064744A1 (en) 2020-04-02
US20220031818A1 (en) 2022-02-03
US20250205318A1 (en) 2025-06-26
JP2022501046A (ja) 2022-01-06
JP7624388B2 (ja) 2025-01-30
SG11202102378WA (en) 2021-04-29
CA3113004A1 (en) 2020-04-02
CN112771159B (zh) 2025-02-11
MX2021003441A (es) 2021-06-15
KR20210091696A (ko) 2021-07-22
AU2019350356A8 (en) 2021-05-27
AU2019350356B9 (en) 2026-01-29
AU2019350356A1 (en) 2021-04-15
IL281762A (en) 2021-05-31
EP3856899A1 (en) 2021-08-04
US12194081B2 (en) 2025-01-14
CN112771159A (zh) 2021-05-07
AU2019350356B2 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
IL289122A (en) polypeptides
IL262482A (en) New polypeptides
GB201719557D0 (en) Polypeptide
IL289119A (en) polypeptides
DK3872428T3 (en) Indvendigt luftstyringssystem
GB201611530D0 (en) Novel polypeptides
GB201820556D0 (en) Novel polypeptides
DK3753395T3 (en) Indvendigt luftstyringssystem
CA184990S (en) Uroflowmeter
GB201707139D0 (en) Polypeptides
EP3841303C0 (de) Mikrogebläse
SG11202102378WA (en) Arginase1 polypeptides
GB201619652D0 (en) Novel polypeptides
DK3650069T3 (en) Trakeostomiventil
GB201810052D0 (en) Polypeptide
DK3578923T3 (en) Navigationssystem
GB201801652D0 (en) Materials
DK3570498T3 (en) Adaptivt hvac-styresystem
GB201817810D0 (en) Modified factor IX polypeptides
GB201811755D0 (en) Polypeptides
GB201807893D0 (en) Polypeptides
GB201807895D0 (en) Polypeptides
GB201807890D0 (en) Polypeptides
GB201911708D0 (en) Polypeptides
GB201805873D0 (en) Novel polypeptides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)